26 Tex. Admin. Code § 306.356 - Responsibilities of the Psychiatric Executive Formulary Committee
(a) The PEFC maintains and updates the HHSC
Psychiatric Drug Formulary by:
(1)
recommending standards of drug use that discourage unnecessary duplication of
therapeutic alternatives and encourage the highest standards of medical and
pharmacy practice;
(2)
periodically reviewing the drugs listed in the formulary to ensure consistency
with need, effectiveness, risk, and cost;
(3) consulting with experts in clinical
pharmacy, pharmacology, and other medical specialties as necessary to
objectively assess drugs under consideration; and
(4) considering the applications submitted in
accordance with §
306.357 of this subchapter
(relating to Adding a Drug to the HHSC Psychiatric Drug Formulary) or as:
(A) presented by committee members; or
(B) submitted by other qualified
persons at the invitation of the PEFC chairperson.
(b) The PEFC may make other
recommendations concerning drug use and policy.
(c) Approval of a drug entity for inclusion
in the HHSC Psychiatric Drug Formulary does not imply approval of all
formulations for that drug. The PEFC designates the formulations that are
allowed for general use by service system components and their contractors.
(d) Approval of a drug formulation
constitutes approval of all brands of the product that have been proven to be
bioequivalent as listed in the then-current Approved Drug Products with
Therapeutic Equivalence Evaluations, published by the United States Food and
Drug Administration.
(e) For a
drug entity that has known bioequivalency problems, the PEFC may limit its use
to a specific brand based on objective clinical pharmacokinetic data.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.